FR14C0064I1 - - Google Patents

Info

Publication number: FR14C0064I1
Authority: FR; France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

Other languages

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-14

Filing date

2014-09-05

Publication date

2014-10-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34699762&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR14C0064(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-05 Application filed filed Critical

2014-10-17 Publication of FR14C0064I1 publication Critical patent/FR14C0064I1/fr

2022-07-08 Application granted granted Critical

2022-07-08 Publication of FR14C0064I2 publication Critical patent/FR14C0064I2/fr

Status Active legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
- C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Hematology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Endocrinology (AREA)
Virology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Neurology (AREA)
Environmental Sciences (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Addiction (AREA)
Otolaryngology (AREA)

FR14C0064C 2001-11-14 2014-09-05 Anticorps anti-il-6, compositions, methodes et utilisations associees Active FR14C0064I2 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US33274301P	2001-11-14	2001-11-14
PCT/US2002/036213 WO2004039826A1 (en)	2001-11-14	2002-10-26	Anti-il-6 antibodies, compositions, methods and uses

Publications (2)

Publication Number	Publication Date
FR14C0064I1 true FR14C0064I1 (nl)	2014-10-17
FR14C0064I2 FR14C0064I2 (fr)	2022-07-08

Family

ID=34699762

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FR14C0064C Active FR14C0064I2 (fr)	2001-11-14	2014-09-05	Anticorps anti-il-6, compositions, methodes et utilisations associees

Country Status (26)

Country	Link
US (7)	US7291721B2 (nl)
EP (2)	EP2308888B1 (nl)
JP (1)	JP2007528691A (nl)
KR (1)	KR20100120246A (nl)
CN (1)	CN100374457C (nl)
AR (1)	AR037384A1 (nl)
AU (1)	AU2002346369B2 (nl)
BE (1)	BE2014C052I2 (nl)
BR (1)	BRPI0214168B8 (nl)
CA (1)	CA2467719C (nl)
CY (3)	CY1114738T1 (nl)
DK (2)	DK2308888T3 (nl)
ES (2)	ES2436206T3 (nl)
FR (1)	FR14C0064I2 (nl)
HK (2)	HK1079213A1 (nl)
IL (1)	IL161968A0 (nl)
LU (1)	LU92543I2 (nl)
MX (1)	MXPA04004671A (nl)
MY (1)	MY142290A (nl)
NL (1)	NL300687I2 (nl)
NO (3)	NO334574B1 (nl)
NZ (1)	NZ533223A (nl)
PT (2)	PT1562968E (nl)
RU (1)	RU2318829C2 (nl)
TW (1)	TWI329019B (nl)
WO (1)	WO2004039826A1 (nl)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20060078533A1 (en) *	2004-10-12	2006-04-13	Omoigui Osemwota S	Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
GB2401040A (en) *	2003-04-28	2004-11-03	Chugai Pharmaceutical Co Ltd	Method for treating interleukin-6 related diseases
AR048210A1 (es) *	2003-12-19	2006-04-12	Chugai Pharmaceutical Co Ltd	Un agente preventivo para la vasculitis.
US8617550B2 (en)	2003-12-19	2013-12-31	Chugai Seiyaku Kabushiki Kaisha	Treatment of vasculitis with IL-6 antagonist
DE602005020743D1 (de) *	2004-02-11	2010-06-02	Warner Lambert Co	Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern
JP4989456B2 (ja) *	2004-02-26	2012-08-01	ベイラーリサーチインスティテュート	関節炎の全身処置のための組成物および方法
ES2400058T3 (es)	2004-09-22	2013-04-05	Cancer Advances, Inc.	Anticuerpos monoclonales para progastrina
WO2006117910A1 (ja)	2005-04-28	2006-11-09	Mochida Pharmaceutical Co., Ltd.	抗血小板膜糖蛋白質ⅵモノクローナル抗体
JP5224707B2 (ja) *	2005-04-28	2013-07-03	持田製薬株式会社	抗血小板膜糖蛋白質ｖｉモノクローナル抗体
PE20061324A1 (es) *	2005-04-29	2007-01-15	Centocor Inc	Anticuerpos anti-il-6, composiciones, metodos y usos
EP1941907B1 (en) *	2005-10-14	2016-03-23	Fukuoka University	Inhibitor of transplanted islet dysfunction in islet transplantation
KR101239051B1 (ko)	2005-10-21	2013-03-04	추가이 세이야쿠 가부시키가이샤	심장질환 치료제
AR057582A1 (es)	2005-11-15	2007-12-05	Nat Hospital Organization	Agentes para suprimir la induccion de linfocitos t citotoxicos
AR057941A1 (es) *	2005-11-25	2007-12-26	Univ Keio	Agentes terapeuticos para el cancer de prostata
ZA200804594B (en)	2005-12-09	2010-08-25	Ucb Pharma Sa	Antibody molecules having specificity for human IL-6
AR057227A1 (es) *	2005-12-09	2007-11-21	Centocor Inc	Metodo para usar antagonistas de il6 con inhibidores del proteasoma
CN101346395A (zh)	2005-12-30	2009-01-14	默克专利有限公司	阻止复合有IL-6Rα的IL-6与GP130结合的抗IL-6抗体
US20090054763A1 (en) *	2006-01-19	2009-02-26	The Regents Of The University Of Michigan	System and method for spectroscopic photoacoustic tomography
CN101370521A (zh)	2006-01-27	2009-02-18	学校法人庆应义塾	伴有脉络膜血管生成的疾病的治疗药
CA2648644C (en)	2006-04-07	2016-01-05	Osaka University	Muscle regeneration promoter
US20070269868A1 (en) *	2006-05-19	2007-11-22	Carvalho Jensen Anne E	Culture method for obtaining a clonal population of antigen-specific B cells
MX2009001110A (es)	2006-08-03	2009-05-11	Vaccinex Inc	Anticuerpos monoclonales anti-il-6 y usos de los mismos.
WO2008042611A2 (en) *	2006-09-29	2008-04-10	Centocor, Inc.	Method of using il6 antagonists with mitoxantrone for prostate cancer
US8414897B1 (en) *	2006-10-02	2013-04-09	The Uab Research Foundation	Pathway for Th-17 cell development and methods utilizing same
JP5631591B2 (ja) *	2006-10-06	2014-11-26	アムジエン・インコーポレーテツド	安定な抗体製剤
AU2012200284B2 (en) *	2006-10-06	2014-03-06	Amgen Inc.	Stable Antibody Formulations
EP2094247B1 (en)	2006-10-20	2022-06-29	Amgen Inc.	Stable polypeptide formulations
US20080123083A1 (en) *	2006-11-29	2008-05-29	The Regents Of The University Of Michigan	System and Method for Photoacoustic Guided Diffuse Optical Imaging
TW200831528A (en)	2006-11-30	2008-08-01	Astrazeneca Ab	Compounds
US8136651B2 (en) *	2007-12-14	2012-03-20	The Procter & Gamble Company	Method and apparatus for orienting articles
US7854932B2 (en)	2006-12-19	2010-12-21	The Board Of Regents Of The University Of Texas System	Immunogenic compositions comprising progastrin and uses thereof
JP2010095445A (ja) *	2006-12-27	2010-04-30	Tokyo Medical & Dental Univ	Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
CN101646459B (zh)	2007-01-23	2014-02-12	国立大学法人信州大学	慢性排斥反应抑制剂
WO2008135419A2 (en) *	2007-05-04	2008-11-13	Charité Universitätsmedizin Berlin	Anti-il-6-agents for improving primary functioning of allogenic grafts
US8062864B2 (en)	2007-05-21	2011-11-22	Alderbio Holdings Llc	Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US7906117B2 (en)	2007-05-21	2011-03-15	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US8252286B2 (en)	2007-05-21	2012-08-28	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat thrombosis
TW201531484A (zh)	2007-05-21	2015-08-16	Alder Biopharmaceuticals Inc	抗ＴＮＦ-α之抗體及其用途
NZ597767A (en) *	2007-05-21	2013-06-28	Bristol Myers Squibb Co	Antibodies to IL-6 and use thereof
AU2008254578B2 (en) *	2007-05-21	2013-06-06	Alderbio Holdings Llc	Novel rabbit antibody humanization methods and humanized rabbit antibodies
US8404235B2 (en)	2007-05-21	2013-03-26	Alderbio Holdings Llc	Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) *	2007-05-21	2012-05-15	Alderbio Holdings Inc.	Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US9701747B2 (en)	2007-05-21	2017-07-11	Alderbio Holdings Llc	Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US20090238825A1 (en) *	2007-05-21	2009-09-24	Kovacevich Brian R	Novel rabbit antibody humanization methods and humanized rabbit antibodies
JP5797403B2 (ja) *	2007-08-03	2015-10-21	エムユーエスシーファウンデーションフォーリサーチディベロップメント	ヒトモノクローナル抗体およびそれを産生する方法
GB0717337D0 (en)	2007-09-06	2007-10-17	Ucb Pharma Sa	Method of treatment
US20100203009A1 (en) *	2007-10-02	2010-08-12	The Uab Research Foundation	Pathway for Th-17 Cell Development and Methods Utilizing Same
KR101601986B1 (ko) *	2007-10-02	2016-03-17	추가이 세이야쿠 가부시키가이샤	인터류킨 6 수용체 저해제를 유효 성분으로 하는 이식편대숙주병 치료제
PT2219452E (pt) *	2007-11-05	2016-01-26	Medimmune Llc	Métodos de tratamento de esclerodermia
PE20091174A1 (es)	2007-12-27	2009-08-03	Chugai Pharmaceutical Co Ltd	Formulacion liquida con contenido de alta concentracion de anticuerpo
KR20220162801A (ko)	2008-04-11	2022-12-08	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복 결합하는 항원 결합 분자
CN102076355B (zh)	2008-04-29	2014-05-07	Abbvie公司	双重可变结构域免疫球蛋白及其用途
CN102089326B (zh)	2008-05-13	2014-12-31	诺维莫尼公司	抗白细胞介素-6/白细胞介素-6受体的抗体及其使用方法
EP3002299A1 (en)	2008-06-03	2016-04-06	AbbVie Inc.	Dual variable domain immunoglobulins and uses thereof
US9109026B2 (en)	2008-06-03	2015-08-18	Abbvie, Inc.	Dual variable domain immunoglobulins and uses thereof
WO2009148148A1 (ja) *	2008-06-05	2009-12-10	国立がんセンター総長が代表する日本国	神経浸潤抑制剤
US8188235B2 (en)	2008-06-18	2012-05-29	Pfizer Inc.	Antibodies to IL-6 and their uses
AU2009266856A1 (en) *	2008-07-02	2010-01-07	Emergent Product Development Seattle, Llc	IL6 immunotherapeutics
KR20110031369A (ko)	2008-07-08	2011-03-25	아보트 러보러터리즈	프로스타글란딘 ｅ2 이원 가변 도메인 면역글로불린 및 이의 용도
TWI440469B (zh) *	2008-09-26	2014-06-11	Chugai Pharmaceutical Co Ltd	Improved antibody molecules
CN104974251A (zh) *	2008-10-20	2015-10-14	Abbvie公司	在抗体纯化过程中的病毒灭活
MX2011004198A (es) *	2008-10-20	2011-05-24	Abbott Lab	Anticerpos que unen a il-12 y metodos para purificar los mismos.
US8062866B2 (en) *	2008-11-13	2011-11-22	Femta Pharmaceuticals, Inc.	Humanized anti-IL-6 antibodies
MX2011005408A (es)	2008-11-25	2011-06-16	Alder Biopharmaceuticals Inc	Antagonistas de il-6 para prevenir o tratar la trombosis.
US9212223B2 (en)	2008-11-25	2015-12-15	Alderbio Holdings Llc	Antagonists of IL-6 to prevent or treat thrombosis
AU2016250477B2 (en) *	2008-11-25	2018-07-05	Vitaeris Inc.	Antagonists of IL-6 to raise albumin and/or lower CRP
US9452227B2 (en)	2008-11-25	2016-09-27	Alderbio Holdings Llc	Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en)	2008-11-25	2015-03-31	Alderbio Holdings Llc	Anti-IL-6 antibodies for the treatment of arthritis
US8323649B2 (en)	2008-11-25	2012-12-04	Alderbio Holdings Llc	Antibodies to IL-6 and use thereof
US8420089B2 (en)	2008-11-25	2013-04-16	Alderbio Holdings Llc	Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) *	2008-11-25	2012-12-25	Alderbio Holdings Llc	Methods of treating anemia using anti-IL-6 antibodies
MX337590B (es) *	2009-01-29	2016-03-11	Medimmune Llc	Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias.
RU2565809C2 (ru) *	2009-03-19	2015-10-20	Чугаи Сейяку Кабусики Кайся	Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
CA2758191C (en) *	2009-04-10	2015-06-30	Ablynx N.V.	Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
NZ598929A (en) *	2009-09-01	2014-05-30	Abbvie Inc	Dual variable domain immunoglobulins and uses thereof
JP2013503919A (ja) *	2009-09-08	2013-02-04	ヤンセンバイオテツク，インコーポレーテツド	癌患者においてヘプシジンを減少させるための抗ｉｌ−６抗体の使用
CN102666875A (zh)	2009-10-15	2012-09-12	雅培制药有限公司	双重可变结构域免疫球蛋白及其用途
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011060076A1 (en) *	2009-11-10	2011-05-19	Amgen Inc.	Anti-c-mpl antibodies
US9775921B2 (en)	2009-11-24	2017-10-03	Alderbio Holdings Llc	Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504030A4 (en)	2009-11-24	2013-06-26	Alderbio Holdings Llc	IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP
US20130052195A1 (en)	2009-12-23	2013-02-28	Emergent Product Development Seattle,LLC	Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
JO3417B1 (ar)	2010-01-08	2019-10-20	Regeneron Pharma	الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
DE102010007562A1 (de)	2010-02-10	2011-08-11	sterna biologicals GmbH & Co KG, 35043	Dermatologische, pharmazeutische Zusammensetzung geeignet für Oligonukleotide
JP2013520476A (ja)	2010-02-26	2013-06-06	ノヴォノルディスクアー／エス	安定な抗体含有組成物
WO2011112873A2 (en) *	2010-03-10	2011-09-15	Paul Tebbey	Extracorporeal immunoadsorption treatment
HRP20221490T1 (hr)	2010-05-28	2023-02-03	Chugai Seiyaku Kabushiki Kaisha	Poboljšanje antitumorskog odgovora t stanice
WO2011147921A1 (en) *	2010-05-28	2011-12-01	Novo Nordisk A/S	Stable multi-dose compositions comprising an antibody and a preservative
US20130224109A1 (en) *	2010-07-20	2013-08-29	Beth Israel Deaconess Medical Center, Inc.	Compositions and methods featuring il-6 and il-21 antagonists
BR112013002578A2 (pt)	2010-08-03	2019-05-14	Abbvie Inc.	imunoglobinas de domínio variável duplo e usos das mesmas
CN103299191B (zh) *	2010-08-13	2016-06-15	莫尔豪斯医学院	中风的生物标记
AU2011293253B2 (en)	2010-08-26	2014-12-11	Abbvie Inc.	Dual variable domain immunoglobulins and uses thereof
DK2643018T3 (da)	2010-11-23	2021-01-18	Vitaeris Inc	Anti-il-6-antistoffer til behandling af oral mucositis
EP2647706B1 (en)	2010-11-30	2023-05-17	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US8696616B2 (en)	2010-12-29	2014-04-15	Ethicon Endo-Surgery, Inc.	Obesity therapy and heart rate variability
CN102161998B (zh) *	2011-01-14	2013-01-09	中国人民解放军军事医学科学院附属医院	基于b7-1-pe40kdel外毒素融合基因的dna疫苗及其用途
US20120189621A1 (en)	2011-01-21	2012-07-26	Yann Dean	Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists
EP2679681B2 (en)	2011-02-25	2023-11-15	Chugai Seiyaku Kabushiki Kaisha	FcgammaRIIB-specific FC antibody
CN110655578A (zh) *	2011-09-30	2020-01-07	中外制药株式会社	诱导针对靶抗原的免疫应答的抗原结合分子
TW201817744A (zh)	2011-09-30	2018-05-16	日商中外製藥股份有限公司	具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047748A1 (ja)	2011-09-30	2013-04-04	中外製薬株式会社	複数の生理活性を有する抗原の消失を促進する抗原結合分子
TWI589299B (zh)	2011-10-11	2017-07-01	再生元醫藥公司	用於治療類風濕性關節炎之組成物及其使用方法
WO2013081143A1 (ja)	2011-11-30	2013-06-06	中外製薬株式会社	免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
TW201333035A (zh)	2011-12-30	2013-08-16	Abbvie Inc	針對ｉｌ－１３及／或ｉｌ－１７之雙特異性結合蛋白
WO2013175276A1 (en) *	2012-05-23	2013-11-28	Argen-X B.V	Il-6 binding molecules
EP2722341B1 (en)	2012-10-22	2017-12-06	Fountain Biopharma Inc.	Antibodies to interleukin-6 and uses thereof
MY194330A (en)	2012-11-01	2022-11-28	Abbvie Inc	Anti-dll4/vegf dual variable domain immunoglobulin and uses thereof
US9168000B2 (en)	2013-03-13	2015-10-27	Ethicon Endo-Surgery, Inc.	Meal detection devices and methods
CN105324396A (zh)	2013-03-15	2016-02-10	艾伯维公司	针对IL-1β和/或IL-17的双重特异性结合蛋白
EP3725311A1 (en)	2014-02-10	2020-10-21	Respivant Sciences GmbH	Methods for the treatment of lung diseases with mast cell stabilizers
JP2017510624A (ja)	2014-02-10	2017-04-13	パタラファーマリミテッドライアビリティカンパニー	肥満細胞安定剤による全身性障害の治療
RU2550262C1 (ru) *	2014-02-28	2015-05-10	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства	Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело
CN105037548B (zh) *	2014-04-21	2018-08-03	上海市免疫学研究所	抗人白介素-6受体β链单克隆抗体、其制备方法和用途
US9840553B2 (en)	2014-06-28	2017-12-12	Kodiak Sciences Inc.	Dual PDGF/VEGF antagonists
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
KR102515796B1 (ko)	2014-12-19	2023-03-30	추가이 세이야쿠 가부시키가이샤	항-c5 항체 및 그의 사용 방법
KR20180054923A (ko)	2014-12-19	2018-05-24	추가이 세이야쿠 가부시키가이샤	항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
MX2017008978A (es)	2015-02-05	2017-10-25	Chugai Pharmaceutical Co Ltd	Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
EP4269440A3 (en)	2015-02-27	2024-02-28	Chugai Seiyaku Kabushiki Kaisha	Composition for treating il-6-related diseases
WO2016195088A1 (ja)	2015-06-04	2016-12-08	国立研究開発法人国立精神・神経医療研究センター	Ｉｌ－６阻害剤を有効成分とする精神疾患治療剤
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
AU2016302768B2 (en)	2015-07-31	2019-08-22	Medimmune Limited	Methods for treating hepcidin-mediated disorders
WO2017027402A1 (en)	2015-08-07	2017-02-16	Patara Pharma, LLC	Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en)	2015-08-07	2019-03-26	Respivant Sciences Gmbh	Methods for the treatment of mast cell related disorders with mast cell stabilizers
US11359009B2 (en)	2015-12-25	2022-06-14	Chugai Seiyaku Kabushiki Kaisha	Anti-myostatin antibodies and methods of use
CA3010056A1 (en)	2015-12-30	2017-07-06	Kodiak Sciences Inc.	Antibodies and conjugates thereof
WO2017177032A2 (en) *	2016-04-07	2017-10-12	Janssen Biotech, Inc.	Treatment of depression using agents that block binding of il-6 to il-6 receptor
KR20190031439A (ko) *	2016-05-05	2019-03-26	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	Il-6 및 cd126을 표적으로 하는 dna 단클론성 항체
US11053308B2 (en)	2016-08-05	2021-07-06	Chugai Seiyaku Kabushiki Kaisha	Method for treating IL-8-related diseases
CN110139646A (zh)	2016-08-31	2019-08-16	瑞思皮万特科学有限责任公司	用于治疗由特发性肺纤维化引起的慢性咳嗽的色甘酸组合物
WO2018067341A1 (en)	2016-10-07	2018-04-12	Patara Pharma, LLC	Cromolyn compositions for treatment of pulmonary fibrosis
WO2018139623A1 (en)	2017-01-30	2018-08-02	Chugai Seiyaku Kabushiki Kaisha	Anti-sclerostin antibodies and methods of use
CA3051865C (en) *	2017-02-01	2023-01-17	Yale University	Treatment of diuretic resistance
US11851486B2 (en)	2017-05-02	2023-12-26	National Center Of Neurology And Psychiatry	Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
EP3624841A4 (en)	2017-06-15	2021-01-27	Cancer Advances, Inc.,	COMPOSITIONS AND METHODS OF INDUCING HUMORAL AND CELLULAR IMMUNITIES AGAINST TUMORS AND CANCER
CN111093710A (zh) *	2017-07-13	2020-05-01	希望之城	硫代磷酸酯缀合的肽及其使用方法
CA3079076A1 (en)	2017-10-18	2019-04-25	Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus	Methods and compounds for improved immune cell therapy
KR20200074160A (ko)	2017-10-20	2020-06-24	가꼬우호우징 효고 이카다이가쿠	항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
CN109867723B (zh) *	2017-12-05	2022-06-17	南京金斯瑞生物科技有限公司	抗人il6单克隆抗体及其制备方法和用途
US20190241650A1 (en)	2018-01-05	2019-08-08	Corvidia Therapeutics, Inc.	Methods for treating il-6 mediated inflammation without immunosuppression
CA3091859A1 (en) *	2018-04-06	2019-10-24	Dana-Farber Cancer Institute, Inc.	Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof
CN109517064B (zh) *	2018-10-10	2020-05-08	北京汇智和源生物技术有限公司	白介素-6的人源化单克隆抗体、其编码基因及应用
SG11202104900SA (en)	2018-11-20	2021-06-29	Univ Cornell	Macrocyclic complexes of radionuclides and their use in radiotherapy of cancer
CN114206442A (zh)	2019-01-31	2022-03-18	赛诺菲生物技术公司	用于治疗幼年特发性关节炎的抗il-6受体抗体
WO2020178193A1 (en)	2019-03-01	2020-09-10	INSERM (Institut National de la Santé et de la Recherche Médicale)	Method of treatment of sarcoidosis
MA55809A (fr)	2019-05-01	2022-03-09	Novo Nordisk As	Formulation d'anticorps anti-il-6
WO2020257586A2 (en)	2019-06-20	2020-12-24	Baxalta Incorporated	Method of treatment with viral-based gene therapy
DE112020002988T5 (de) *	2019-08-05	2022-05-19	Agency For Science, Technology And Research	Kombinationstherapie zur erzielung einer erhöhten antimikrobiellen aktivität
EP4041312A4 (en)	2019-10-10	2023-12-20	Kodiak Sciences Inc.	METHOD FOR TREATING AN EYE DISORDER
WO2022157493A1 (en)	2021-01-21	2022-07-28	Eusa Pharma (Uk) Limited	Method for treating il-6 associated histiocytic and lymphoproliferative disorders
WO2022162358A1 (en)	2021-01-28	2022-08-04	Eusa Pharma (Uk) Limited	Methods for treating rare disorders with anti-il-6 therapy
WO2022162354A1 (en)	2021-01-28	2022-08-04	Eusa Pharma (Uk) Limited	Methods for treating rare disorders with anti-il-6 therapy
WO2022162357A1 (en)	2021-01-28	2022-08-04	Eusa Pharma (Uk) Limited	Methods for treating igg4-related disease with anti-il-6 therapy
WO2022162352A1 (en)	2021-01-28	2022-08-04	Eusa Pharma (Uk) Limited	Methods for treating rare disorders with anti-il-6 therapy
WO2022162351A1 (en)	2021-01-28	2022-08-04	Eusa Pharma (Uk) Limited	Methods for treating rare disorders with anti-il-6 therapy
CN113057142B (zh) *	2021-03-30	2022-12-09	四川大学华西医院	一种视网膜内和/或视网膜下纤维化动物模型的构建方法
CN114478672A (zh) *	2022-01-27	2022-05-13	浙江仙居君业药业有限公司	一种he3286的合成方法
CN117247451B (zh) *	2023-11-17	2024-02-09	中国人民解放军军事科学院军事医学研究院	一种针对人白介素6蛋白的单域抗体及其应用

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4309989A (en)	1976-02-09	1982-01-12	The Curators Of The University Of Missouri	Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr)	1976-10-23	1978-07-21	Choay Sa	Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
FR2413974A1 (fr)	1978-01-06	1979-08-03	David Bernard	Sechoir pour feuilles imprimees par serigraphie
US5326859A (en)	1979-10-30	1994-07-05	Juridical Foundation, Japanese Foundation For Cancer Research	DNA and recombinant plasmid
IL58765A (en)	1979-11-21	1986-09-30	Yeda Res & Dev	Process for the production of essentially pure messenger rna of human fibroblast interferon and process for the production of interferon beta
US5554513A (en)	1979-11-21	1996-09-10	Yeda Research & Development Co. Ltd.	Production of recombinant human interferon-beta2
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4656134A (en)	1982-01-11	1987-04-07	Board Of Trustees Of Leland Stanford Jr. University	Gene amplification in eukaryotic cells
US5149636A (en)	1982-03-15	1992-09-22	Trustees Of Columbia University In The City Of New York	Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en) *	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965188A (en)	1986-08-22	1990-10-23	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en)	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US6492107B1 (en)	1986-11-20	2002-12-10	Stuart Kauffman	Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
GB2183661B (en)	1985-03-30	1989-06-28	Marc Ballivet	Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
SE448277B (sv)	1985-04-12	1987-02-09	Draco Ab	Indikeringsanordning vid en doseringsanordning for lekemedel
US4766067A (en)	1985-05-31	1988-08-23	President And Fellows Of Harvard College	Gene amplification
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5618920A (en)	1985-11-01	1997-04-08	Xoma Corporation	Modular assembly of antibody genes, antibodies prepared thereby and use
DE3600905A1 (de)	1986-01-15	1987-07-16	Ant Nachrichtentech	Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen
GB8601597D0 (en)	1986-01-23	1986-02-26	Wilson R H	Nucleotide sequences
US4800159A (en)	1986-02-07	1989-01-24	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences
SE453566B (sv)	1986-03-07	1988-02-15	Draco Ab	Anordning vid pulverinhalatorer
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US4767402A (en)	1986-07-08	1988-08-30	Massachusetts Institute Of Technology	Ultrasound enhancement of transdermal drug delivery
US4925673A (en)	1986-08-18	1990-05-15	Clinical Technologies Associates, Inc.	Delivery systems for pharmacological agents encapsulated with proteinoids
US4889818A (en)	1986-08-22	1989-12-26	Cetus Corporation	Purified thermostable enzyme
US4795699A (en)	1987-01-14	1989-01-03	President And Fellows Of Harvard College	T7 DNA polymerase
US4921794A (en)	1987-01-14	1990-05-01	President And Fellows Of Harvard College	T7 DNA polymerase
EP0832981A1 (en)	1987-02-17	1998-04-01	Pharming B.V.	DNA sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en)	1987-06-23	1989-10-10	Biogen, Inc.	Isolation of exogenous recombinant proteins from the milk of transgenic mammals
IL88375A (en)	1988-11-14	1995-07-31	Yeda Res & Dev	Monoclonal antibodies that specifically bind interferon-bia 2 natural and recombinant and a natural and recombinant interferon-beta 2 purification method and method
US6010902A (en)	1988-04-04	2000-01-04	Bristol-Meyers Squibb Company	Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US4956288A (en)	1988-04-22	1990-09-11	Biogen, Inc.	Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5130238A (en)	1988-06-24	1992-07-14	Cangene Corporation	Enhanced nucleic acid amplification process
US5601819A (en)	1988-08-11	1997-02-11	The General Hospital Corporation	Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5091310A (en)	1988-09-23	1992-02-25	Cetus Corporation	Structure-independent dna amplification by the polymerase chain reaction
US5066584A (en)	1988-09-23	1991-11-19	Cetus Corporation	Methods for generating single stranded dna by the polymerase chain reaction
US5142033A (en)	1988-09-23	1992-08-25	Hoffmann-La Roche Inc.	Structure-independent DNA amplification by the polymerase chain reaction
US6682896B1 (en)	1988-10-14	2004-01-27	Schering Aktiengesellschaft	Peptides representing epitopic sites on r-IFN-β, antibodies thereto and uses thereof
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US4994370A (en)	1989-01-03	1991-02-19	The United States Of America As Represented By The Department Of Health And Human Services	DNA amplification technique
US5266491A (en)	1989-03-14	1993-11-30	Mochida Pharmaceutical Co., Ltd.	DNA fragment and expression plasmid containing the DNA fragment
DE3909708A1 (de)	1989-03-23	1990-09-27	Boehringer Mannheim Gmbh	Verfahren zur herstellung bispezifischer antikoerper
WO1990014443A1 (en)	1989-05-16	1990-11-29	Huse William D	Co-expression of heteromeric receptors
CA2016841C (en)	1989-05-16	1999-09-21	William D. Huse	A method for producing polymers having a preselected activity
CA2016842A1 (en)	1989-05-16	1990-11-16	Richard A. Lerner	Method for tapping the immunological repertoire
ES2096590T3 (es)	1989-06-29	1997-03-16	Medarex Inc	Reactivos biespecificos para la terapia del sida.
EP0506855A1 (en)	1989-12-15	1992-10-07	Chiron Corporation	Cytokine antibody for the treatment of sepsis
US5580575A (en)	1989-12-22	1996-12-03	Imarx Pharmaceutical Corp.	Therapeutic drug delivery systems
US6075181A (en) *	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5942220A (en)	1990-03-16	1999-08-24	Chiron Corporation	Inhibitor of cytokine activity and applications thereof
US5358673A (en) *	1990-02-15	1994-10-25	3D Systems, Inc.	Applicator device and method for dispensing a liquid medium in a laser modeling machine
TW212184B (nl)	1990-04-02	1993-09-01	Takeda Pharm Industry Co Ltd
ATE204902T1 (de)	1990-06-29	2001-09-15	Large Scale Biology Corp	Melaninproduktion durch transformierte mikroorganismen
US5580734A (en)	1990-07-13	1996-12-03	Transkaryotic Therapies, Inc.	Method of producing a physical map contigous DNA sequences
EP0557300B1 (en)	1990-10-29	1997-11-19	Chiron Corporation	Bispecific antibodies, method of production, and uses thereof
US5582996A (en)	1990-12-04	1996-12-10	The Wistar Institute Of Anatomy & Biology	Bifunctional antibodies and method of preparing same
US5404871A (en)	1991-03-05	1995-04-11	Aradigm	Delivery of aerosol medications for inspiration
EP0575545B1 (en)	1991-03-15	2003-05-21	Amgen Inc.	Pegylation of polypeptides
DE4118120A1 (de)	1991-06-03	1992-12-10	Behringwerke Ag	Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5637481A (en)	1993-02-01	1997-06-10	Bristol-Myers Squibb Company	Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ES2284226T3 (es)	1991-07-02	2007-11-01	Nektar Therapeutics	Dispositivo para proporcionar medicamentos en aerosol.
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
US5641670A (en)	1991-11-05	1997-06-24	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US5968502A (en)	1991-11-05	1999-10-19	Transkaryotic Therapies, Inc.	Protein production and protein delivery
US5932448A (en)	1991-11-29	1999-08-03	Protein Design Labs., Inc.	Bispecific antibody heterodimers
CA2507749C (en)	1991-12-13	2010-08-24	Xoma Corporation	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE4207475A1 (de)	1992-03-10	1993-09-16	Goldwell Ag	Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung
EP0583020B1 (en) *	1992-05-20	1998-08-12	Eastman Kodak Company	Photographic material with improved granularity
AU4829593A (en)	1992-09-23	1994-04-12	Fisons Plc	Inhalation device
AU5322494A (en)	1992-10-02	1994-04-26	Trustees Of Dartmouth College	Bispecific reagents for redirected targeting of low density lipoprotein
ES2127837T3 (es)	1992-10-19	1999-05-01	Dura Pharma Inc	Inhalador para polvo seco.
WO1994009138A1 (en)	1992-10-20	1994-04-28	Cetus Oncology Corporation	Interleukin-6 receptor antagonists
US5643252A (en)	1992-10-28	1997-07-01	Venisect, Inc.	Laser perforator
US5849695A (en)	1993-01-13	1998-12-15	The Regents Of The University Of California	Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
DE69414369T2 (de)	1993-01-19	1999-05-27	Glaxo Group Ltd	Aerosol-spender und verfahren zu seiner herstellung
EP1978095A1 (en)	1993-02-12	2008-10-08	The Board Of Trustees Of The Leland Stanford Junior University	Chimeric receptor proteins for controlling signal transduction and ligands binding thereto
JP3525221B2 (ja)	1993-02-17	2004-05-10	味の素株式会社	免疫抑制剤
US5888511A (en) *	1993-02-26	1999-03-30	Advanced Biotherapy Concepts, Inc.	Treatment of autoimmune diseases, including AIDS
JPH08509612A (ja)	1993-04-26	1996-10-15	ジェンファームインターナショナルインコーポレイテッド	異種抗体を産生することができるトランスジェニック非ヒト動物
WO1994028159A1 (fr)	1993-05-31	1994-12-08	Chugai Seiyaku Kabushiki Kaisha	Anticorps humain reconstruit contre l'interleukine-6 humaine
US5789552A (en)	1993-06-23	1998-08-04	Istituto Di Ricerche Di Biologica Molecolare P. Angeletti S.P.A.	Interleukin-6 receptor antagonists
US5888510A (en)	1993-07-21	1999-03-30	Chugai Seiyaku Kabushiki Kaisha	Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
FR2707882B1 (fr)	1993-07-23	1997-08-01	Immunotech Sa	Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
US5514670A (en)	1993-08-13	1996-05-07	Pharmos Corporation	Submicron emulsions for delivery of peptides
DE4337197C1 (de)	1993-10-30	1994-08-25	Biotest Pharma Gmbh	Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5814599A (en)	1995-08-04	1998-09-29	Massachusetts Insitiute Of Technology	Transdermal delivery of encapsulated drugs
US5827690A (en)	1993-12-20	1998-10-27	Genzyme Transgenics Corporatiion	Transgenic production of antibodies in milk
DE69527050T2 (de)	1994-03-07	2003-02-13	Medarex Inc	Bispezifische moleküle mit klinischer verwendbarkeit
US5641657A (en)	1994-05-19	1997-06-24	Human Genome Sciences, Inc.	DNA encoding an interleukin-6 splice variant
US8017121B2 (en) *	1994-06-30	2011-09-13	Chugai Seiyaku Kabushika Kaisha	Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
IT1274782B (it)	1994-12-14	1997-07-24	Angeletti P Ist Richerche Bio	Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
ES2170815T5 (es) *	1994-12-29	2012-11-14	Chugai Seiyaku Kabushiki Kaisha	Uso de un anticuerpo PM-1 o de un anticuerpo MH166 para potenciar el efecto antitumoral de cisplatino o carboplatino
WO1996025174A1 (fr)	1995-02-13	1996-08-22	Chugai Seiyaku Kabushiki Kaisha	Inhibiteur de decomposition des proteines musculaires contenant un anticorps du recepteur de l'interleukine-6
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US6037453A (en)	1995-03-15	2000-03-14	Genentech, Inc.	Immunoglobulin variants
IT1276555B1 (it)	1995-04-28	1997-11-03	Angeletti P Ist Richerche Bio	Antagonisti di interluchina-6 umana del tutto incapaci di formare un legame con gp 130, e loro uso per la preparazione di composizioni
US5730723A (en)	1995-10-10	1998-03-24	Visionary Medical Products Corporation, Inc.	Gas pressured needle-less injection device and method
GB9526100D0 (en)	1995-12-20	1996-02-21	Intersurgical Ltd	Nebulizer
CN1213974A (zh)	1996-01-03	1999-04-14	葛兰素集团有限公司	吸入器具
US5714352A (en)	1996-03-20	1998-02-03	Xenotech Incorporated	Directed switch-mediated DNA recombination
US5854398A (en)	1996-07-25	1998-12-29	The Trustees Of Columbia University In The City Of New York	Kaposi's sarcoma-associated herpesvirus (KSHV) interleukin 6 (IL-6) and uses thereof
ES2169299T3 (es)	1996-09-03	2002-07-01	Gsf Forschungszentrum Umwelt	Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos.
US5879681A (en)	1997-02-07	1999-03-09	Emisphere Technolgies Inc.	Compounds and compositions for delivering active agents
US5921447A (en)	1997-02-13	1999-07-13	Glaxo Wellcome Inc.	Flow-through metered aerosol dispensing apparatus and method of use thereof
JPH10302563A (ja) *	1997-04-22	1998-11-13	Yazaki Corp	グロメット
IL120943A (en)	1997-05-29	2004-03-28	Univ Ben Gurion	A system for administering drugs through the skin
US6011288A (en) *	1997-12-22	2000-01-04	Taiwan Semiconductor Manufacturing Company, Ltd.	Flash memory cell with vertical channels, and source/drain bus lines
US7098309B2 (en) *	1998-12-23	2006-08-29	Merck & Co., Inc.	Recombinant hepatitis B surface antigen
US20020010320A1 (en) *	1999-04-05	2002-01-24	James W. Fett	Chemeric and humanized antibodies to angiogenin
TWI373343B (en)	2000-02-10	2012-10-01	Abbott Gmbh & Co Kg	Antibodies that bind human interleukin-18 and methods of making and using
JP5470817B2 (ja)	2008-03-10	2014-04-16	日産自動車株式会社	電池用電極およびこれを用いた電池、並びにその製造方法
TWI503850B (zh)	2013-03-22	2015-10-11	Polytronics Technology Corp	過電流保護元件
TWI510996B (zh)	2013-10-03	2015-12-01	Acer Inc	控制觸控面板的方法以及使用該方法的可攜式電腦
US9816280B1 (en)	2016-11-02	2017-11-14	Matthew Reitnauer	Portable floor

2002
- 2002-10-26 KR KR1020107024321A patent/KR20100120246A/ko not_active Application Discontinuation
- 2002-10-26 JP JP2004548246A patent/JP2007528691A/ja not_active Withdrawn
- 2002-10-26 PT PT27844364T patent/PT1562968E/pt unknown
- 2002-10-26 PT PT101790491T patent/PT2308888T/pt unknown
- 2002-10-26 WO PCT/US2002/036213 patent/WO2004039826A1/en active Application Filing
- 2002-10-26 RU RU2004114882/13A patent/RU2318829C2/ru active
- 2002-10-26 EP EP10179049.1A patent/EP2308888B1/en not_active Expired - Lifetime
- 2002-10-26 BR BRPI0214168A patent/BRPI0214168B8/pt active IP Right Grant
- 2002-10-26 CA CA2467719A patent/CA2467719C/en not_active Expired - Lifetime
- 2002-10-26 EP EP02784436.4A patent/EP1562968B1/en not_active Expired - Lifetime
- 2002-10-26 MX MXPA04004671A patent/MXPA04004671A/es active IP Right Grant
- 2002-10-26 US US10/280,716 patent/US7291721B2/en active Active
- 2002-10-26 AU AU2002346369A patent/AU2002346369B2/en active Active
- 2002-10-26 DK DK10179049.1T patent/DK2308888T3/en active
- 2002-10-26 ES ES02784436T patent/ES2436206T3/es not_active Expired - Lifetime
- 2002-10-26 ES ES10179049.1T patent/ES2624547T3/es not_active Expired - Lifetime
- 2002-10-26 DK DK02784436.4T patent/DK1562968T3/da active
- 2002-10-26 NZ NZ533223A patent/NZ533223A/en not_active IP Right Cessation
- 2002-10-26 CN CNB028298039A patent/CN100374457C/zh not_active Expired - Lifetime
- 2002-10-26 IL IL16196802A patent/IL161968A0/xx active Protection Beyond IP Right Term
- 2002-11-13 TW TW091133208A patent/TWI329019B/zh active
- 2002-11-13 MY MYPI20024224A patent/MY142290A/en unknown
- 2002-11-14 AR ARP020104379A patent/AR037384A1/es active IP Right Grant
2004
- 2004-06-10 NO NO20042418A patent/NO334574B1/no not_active IP Right Cessation
2005
- 2005-12-08 HK HK05111243.7A patent/HK1079213A1/xx not_active IP Right Cessation
2006
- 2006-03-22 HK HK06103634A patent/HK1083509A1/xx not_active IP Right Cessation
2007
- 2007-08-01 US US11/832,323 patent/US7612182B2/en not_active Expired - Lifetime
- 2007-10-30 US US11/927,925 patent/US7833786B2/en not_active Expired - Lifetime
2009
- 2009-07-23 US US12/507,962 patent/US7955597B2/en not_active Expired - Fee Related
2011
- 2011-05-11 US US13/105,152 patent/US20110218329A1/en not_active Abandoned
- 2011-12-21 US US13/332,973 patent/US20120096569A1/en not_active Abandoned
2013
- 2013-07-25 NO NO20131043A patent/NO20131043L/no not_active Application Discontinuation
- 2013-09-19 CY CY20131100821T patent/CY1114738T1/el unknown
2014
- 2014-01-29 US US14/167,384 patent/US20140141013A1/en not_active Abandoned
- 2014-09-04 BE BE2014C052C patent/BE2014C052I2/nl unknown
- 2014-09-05 LU LU92543C patent/LU92543I2/fr unknown
- 2014-09-05 FR FR14C0064C patent/FR14C0064I2/fr active Active
- 2014-09-05 CY CY2014038C patent/CY2014038I1/el unknown
- 2014-09-05 NL NL300687C patent/NL300687I2/nl unknown
- 2014-09-24 NO NO2014025C patent/NO2014025I2/no unknown
2017
- 2017-05-12 CY CY20171100514T patent/CY1118955T1/el unknown

Also Published As

Publication number	Publication date
US7955597B2 (en)	2011-06-07
AR037384A1 (es)	2004-11-03
US7612182B2 (en)	2009-11-03
FR14C0064I2 (fr)	2022-07-08
BE2014C052I2 (nl)	2022-02-01
US20080312172A1 (en)	2008-12-18
US7291721B2 (en)	2007-11-06
IL161968A0 (en)	2005-11-20
CN100374457C (zh)	2008-03-12
EP1562968A4 (en)	2006-08-23
CY1118955T1 (el)	2018-01-10
EP2308888B1 (en)	2017-03-01
US20140141013A1 (en)	2014-05-22
NO2014025I1 (no)	2014-09-24
MY142290A (en)	2010-11-15
DK2308888T3 (en)	2017-06-06
DK1562968T3 (da)	2013-10-28
JP2007528691A (ja)	2007-10-18
RU2318829C2 (ru)	2008-03-10
RU2004114882A (ru)	2005-04-20
EP2308888A1 (en)	2011-04-13
AU2002346369A1 (en)	2004-05-25
CN1694894A (zh)	2005-11-09
US20110218329A1 (en)	2011-09-08
LU92543I2 (fr)	2014-11-05
NL300687I2 (nl)	2016-10-11
PT2308888T (pt)	2017-05-03
ES2436206T3 (es)	2013-12-27
NO20131043L (no)	2004-08-05
US7833786B2 (en)	2010-11-16
NO334574B1 (no)	2014-04-14
AU2002346369B2 (en)	2009-08-27
CA2467719A1 (en)	2003-05-13
US20070292420A1 (en)	2007-12-20
MXPA04004671A (es)	2005-08-25
TW200301134A (en)	2003-07-01
ES2624547T3 (es)	2017-07-14
KR20100120246A (ko)	2010-11-12
TWI329019B (en)	2010-08-21
HK1083509A1 (en)	2006-07-07
BRPI0214168B1 (pt)	2020-11-10
NO2014025I2 (no)	2014-09-24
NO20042418L (no)	2004-08-05
US20090291084A1 (en)	2009-11-26
HK1079213A1 (en)	2006-03-31
NZ533223A (en)	2007-04-27
CA2467719C (en)	2015-03-17
CY2014038I2 (el)	2015-12-09
BR0214168A (pt)	2004-09-14
BRPI0214168B8 (pt)	2021-05-25
CY2014038I1 (el)	2015-12-09
EP1562968B1 (en)	2013-08-21
WO2004039826A1 (en)	2004-05-13
PT1562968E (pt)	2013-10-23
CY1114738T1 (el)	2015-12-09
US20060188502A1 (en)	2006-08-24
EP1562968A1 (en)	2005-08-17
US20120096569A1 (en)	2012-04-19

Publication	Publication Date	Title
BE2022C531I2 (nl)	2022-08-09
BE2022C502I2 (nl)	2023-04-12
BE2022C547I2 (nl)	2022-10-19
BE2017C057I2 (nl)	2022-02-01
BE2017C051I2 (nl)	2021-11-22
BE2017C032I2 (nl)	2021-07-19
BE2015C046I2 (nl)	2021-07-19
FR14C0064I1 (nl)	2014-10-17
BE2014C036I2 (nl)	2021-11-22
BE2014C026I2 (nl)	2021-11-22
BE2014C004I2 (nl)	2021-11-22
BE2014C006I2 (nl)	2021-02-04
BE2017C050I2 (nl)	2021-11-22
BE2011C034I2 (nl)	2021-11-22
BE2007C047I2 (nl)	2021-06-04
AU2002307149A8 (nl)	2002-10-21
BRPI0209186B1 (nl)	2012-11-13
JP2002176345A5 (nl)	2007-08-16
BE2014C008I2 (nl)	2021-02-04
BRPI0204884A2 (nl)	2004-06-15
BE2016C021I2 (nl)	2021-03-23
BE2017C059I2 (nl)	2021-11-22
JP2002137798A5 (nl)	2008-09-25
HU0201356D0 (nl)	2002-06-29
JP2002117985A5 (nl)	2008-09-04